NCT00035048已完成3 期
A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients With Major Depressive Disorder
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 540
- 主要终点
- HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability
研究概览
简要总结
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
详细描述
The duration of treatment is 10 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Major Depressive Disorder
排除标准
- 未提供
结局指标
主要结局
HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability
时间窗: After 10 weeks & 6-10 months
次要结局
- CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; MADRS total score change at Month 6, HAMA total score change at Month 6(6 Months)
研究者
相似试验
已完成
3 期
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive DisorderNCT00048594Merck Sharp & Dohme LLC800
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive DisorderNCT00035282Merck Sharp & Dohme LLC450
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)Major Depressive DisorderNCT00034983Merck Sharp & Dohme LLC900
已完成
2 期
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT00601107Genzyme, a Sanofi Company111
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive DisorderNCT00035295Merck Sharp & Dohme LLC584